HRMY Harmony Biosciences Holdings, Inc. — QuoTrend

Analyst Ratings

Date	Action	Analyst	Rating	Target
Feb-23-26	Reiterated	Deutsche Bank	Buy	$31
Feb-19-26	Reiterated	Mizuho Securities		$46 → $50
Feb-11-26	Downgrade	UBS	Buy → Neutral	$43 → $46
Jan-08-26	Reiterated	Truist Financial		$48 → $45
Dec-01-25	Reiterated	Mizuho Securities		$39 → $46
Nov-24-25	Reiterated	Oppenheimer	Outperform	$56 → $62
Oct-29-25	Reiterated	Mizuho Securities		$35 → $36
Oct-15-25	Reiterated	UBS	Buy	$48 → $43
Sep-25-25	Reiterated	H.C. Wainwright		$70 → $55
Jul-10-25	Resumed	Goldman Sachs	Neutral	$28 → $33

Financial Statements

DataTimeframe

Line Item (USD, M)		TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue		898	868	715	Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A		212	198	157
Gross Profit		688	670	558
Selling, General and Administrative Excl. Other		274	272	221
Research and Development		224	190	146
Other Operating Expense		1	0	0
Operating Income		189	208	191
Interest Expense		15	15	17
Unusual Expense		—	—	—
Non-Operating Income (Expense)		-19	-21	-18
Net Income Before Taxes		198	215	192
Income Taxes		52	56	46
Consolidated Net Income		145	159	145
Net Income From Continuing Operations		145	159	145
Net Income		145	159	145
EPS (Recurring)		2.52	2.76	2.56
EPS (Basic, Before Extraordinaries)		2.52	2.76	2.56
EPS (Diluted)		2.48	2.71	2.51
EBITDA		233	255	233
Other After Tax Adjustments		—	—	—
Stock Option Compensation Expense		—	—	—
Price To Earnings Ratio		13.42	13.81	—
Price To Sales Ratio		2.15	2.46	—
Gross Margin		76.61	77.19	78.04
Operating Margin		21.05	23.96	26.71
Net Margin		16.15	18.32	20.28
Shares Outstanding		58	57	57
Market Capitalization		1,930	2,133	—
Operating Lease Expense		—	—	—

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Budur Kumar	CHIEF MEDICAL OFFICER	May 01 '26	Option Exercise	0.00	37,500	0	37,500	May 18 12:00 AM
Zaeske Adam H.	CHIEF COMMERCIAL OFFICER	Apr 07 '26	Option Exercise	0.00	15,000	0	7,500	Apr 09 12:00 AM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	37.15	3,746	139,171	24,521	Jan 28 12:00 AM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 25 '26	Option Exercise	0.00	26,000	0	39,000	Jan 26 12:00 AM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 25 '26	Option Exercise	0.00	9,450	0	14,175	Jan 26 12:00 AM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 25 '26	Option Exercise	0.00	5,324	0	7,988	Jan 26 12:00 AM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 25 '26	Option Exercise	0.00	5,200	0	7,800	Jan 26 12:00 AM
Budur Kumar	CHIEF MEDICAL OFFICER	Jan 24 '26	Option Exercise	0.00	4,376	0	4,175	Jan 26 12:00 AM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 24 '26	Option Exercise	0.00	7,626	0	7,625	Jan 26 12:00 AM
Serafin Andrew	CHIEF STRATEGY OFFICER	Jan 24 '26	Option Exercise	0.00	5,000	0	5,000	Jan 26 12:00 AM
Dayno Jeffrey M.	PRESIDENT, CEO	Jan 24 '26	Option Exercise	0.00	21,000	0	21,000	Jan 26 12:00 AM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Jan 15 '26	Sale	35.92	20,961	752,833	0	Jan 20 12:00 AM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Option Exercise	8.22	40,000	328,800	20,000	Dec 17 12:00 AM
Dayno Jeffrey M.	PRESIDENT, CEO	Dec 12 '25	Sale	40.11	5,933	237,957	0	Dec 17 12:00 AM
Kapadia Sandip	CHIEF FINANCIAL OFFICER	Dec 05 '25	Option Exercise	29.03	40,000	1,161,200	185,000	Dec 09 12:00 AM